Shanghai Rendu Biotechnology Co., Ltd. (SHA:688193)
China · Delayed Price · Currency is CNY 48.78
+0.79 (1.65%)
At close: Aug 4, 2026
SHA:688193 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 160.53 | 159.14 | 175.91 | 162.76 | 293.94 | 286.13 |
Other Revenue | 2.81 | 2.81 | 1.44 | 1.65 | 9.91 | 6.18 |
| 163.34 | 161.94 | 177.35 | 164.41 | 303.85 | 292.31 | |
Revenue Growth | -5.71% | -8.69% | 7.87% | -45.89% | 3.95% | 16.97% |
Cost of Revenue | 38.03 | 37.51 | 39.1 | 32.09 | 106.11 | 74.38 |
Gross Profit | 125.3 | 124.43 | 138.25 | 132.32 | 197.74 | 217.93 |
Selling, General & Admin | 105.77 | 109.59 | 119.98 | 118.1 | 155.04 | 127.4 |
Research & Development | 32.48 | 34.04 | 38.45 | 40.54 | 33.89 | 26.12 |
Other Operating Expenses | -0.55 | -1.53 | -2.03 | -0.69 | 0.86 | 0.83 |
Operating Expenses | 125.54 | 129.82 | 173.23 | 158.55 | 192.72 | 155.35 |
Operating Income | -0.24 | -5.38 | -34.98 | -26.23 | 5.02 | 62.58 |
Interest Expense | -0.22 | -0.24 | -0.29 | -0.43 | -0.36 | -0.26 |
Interest & Investment Income | 12.75 | 11.71 | 17.76 | 15.65 | 12.57 | 3.21 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | -0.01 | -0.12 | 0.56 | -0.2 |
Other Non Operating Income (Expenses) | -0.14 | -0.26 | -0.3 | -0.06 | 0.13 | -0.15 |
EBT Excluding Unusual Items | 12.06 | 5.74 | -17.83 | -11.19 | 17.93 | 65.18 |
Gain (Loss) on Sale of Investments | 2.26 | 3.62 | -0.24 | 0.66 | 0.98 | - |
Gain (Loss) on Sale of Assets | -0.48 | -0.49 | -0.69 | -0.05 | 0.14 | 0.76 |
Asset Writedown | 0.25 | - | - | -0.34 | -1.19 | -0.38 |
Other Unusual Items | 1.04 | 1.35 | 3.54 | 15.68 | 8.82 | 6.89 |
Pretax Income | 15.13 | 10.22 | -15.22 | 4.76 | 26.68 | 72.44 |
Income Tax Expense | 1.27 | 0.13 | -7.41 | -3.5 | 3.35 | 7.82 |
Net Income | 13.86 | 10.09 | -7.81 | 8.26 | 23.33 | 64.62 |
Net Income to Common | 13.86 | 10.09 | -7.81 | 8.26 | 23.33 | 64.62 |
Net Income Growth | - | - | - | -64.60% | -63.89% | 5.28% |
Shares Outstanding (Basic) | 39 | 39 | 39 | 39 | 38 | 30 |
Shares Outstanding (Diluted) | 39 | 39 | 39 | 39 | 38 | 30 |
Shares Change | 0.21% | -0.67% | -0.68% | 2.83% | 26.08% | 0.95% |
EPS (Basic) | 0.36 | 0.26 | -0.20 | 0.21 | 0.62 | 2.15 |
EPS (Diluted) | 0.36 | 0.26 | -0.20 | 0.21 | 0.61 | 2.13 |
EPS Growth | - | - | - | -65.57% | -71.36% | 4.41% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 8.65 | 15.33 | 13.86 | -3.2 | -25.31 | 27.97 |
Free Cash Flow Per Share | 0.22 | 0.40 | 0.35 | -0.08 | -0.66 | 0.92 |
Dividend Per Share | 1.150 | 1.150 | 0.200 | 0.200 | 0.125 | - |
Dividend Growth | 475.00% | 475.00% | 0% | 60.00% | - | - |
Gross Margin | 76.71% | 76.84% | 77.95% | 80.48% | 65.08% | 74.56% |
Operating Margin | -0.15% | -3.32% | -19.73% | -15.95% | 1.65% | 21.41% |
Profit Margin | 8.49% | 6.23% | -4.41% | 5.02% | 7.68% | 22.11% |
Free Cash Flow Margin | 5.30% | 9.47% | 7.82% | -1.94% | -8.33% | 9.57% |
EBITDA | 13.08 | 8.1 | -20.86 | -13.43 | 17.42 | 70.93 |
EBITDA Margin | 8.01% | 5.00% | -11.76% | -8.17% | 5.73% | 24.27% |
D&A For EBITDA | 13.32 | 13.48 | 14.12 | 12.8 | 12.4 | 8.35 |
EBIT | -0.24 | -5.38 | -34.98 | -26.23 | 5.02 | 62.58 |
EBIT Margin | -0.15% | -3.32% | -19.73% | -15.95% | 1.65% | 21.41% |
Effective Tax Rate | 8.41% | 1.29% | - | - | 12.56% | 10.80% |
Revenue as Reported | 163.34 | 161.94 | 177.35 | 164.41 | 303.85 | 292.31 |